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The shift in industry toward connected and continuous monoclonal antibody (mAb) processing has necessitated 
the development of novel approaches to improve or replace traditional unit operations.  A bottleneck in 
connected processing is the viral inactivation step, which is typically accomplished by holding the Protein A 
elution material in a large vessel for a fixed period of time.  There are multiple factors to consider when 
translating this inherently batch operation into a continuous mode.  In this presentation, we will describe our 
efforts to develop a comprehensive understanding of virus inactivation kinetics and the impact of buffer/mAb 
composition on the virus inactivation process.  Based on this knowledge, a flow-through system can be 
designed to achieve the desired virus clearance capabilities.  We will also describe how such in-line virus 
inactivation processes may lead to shorter processing times, reduced facility footprint, and simpler integration 
with adjacent processing operations.  Technologies such as in-line virus inactivation are expected to play an 
important role in the next generation mAb processing toolbox. 
